We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
inducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma.
- Authors
Voskens, Caroline J.; Sewell, Duane; Hertzano, Ronna; DeSanto, Jennifer; Rollins, Sandra; Lee, Myounghee; Taylor, Rodney; Wolf, Jeffrey; Suntharalingam, Mohan; Gastman, Brian; Papadimitriou, John C.; Lu, Changwan; Tan, Ming; Morales, Robert; Cullen, Kevin; Celis, Esteban; Mann, Dean; Strome, Scott E.
- Abstract
Background We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a 'penetrin' peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled. Methods Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections. Results Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced. Conclusion This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN. © 2012 Wiley Periodicals, Inc. Head Neck, 2012
- Subjects
PAPILLOMAVIRUSES; HEAD &; neck cancer treatment; VACCINATION; PILOT projects; SQUAMOUS cell carcinoma; GRANULOCYTE-macrophage colony-stimulating factor; IMMUNOREGULATION
- Publication
Head & Neck, 2012, Vol 34, Issue 12, p1734
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.22004